These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38185982)

  • 1. Association Between Remnant Cholesterol and Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention.
    Luo B; Huang X; Peng Y; Luo H; Chen L; Lin Y
    Angiology; 2024 Jan; ():33197231225862. PubMed ID: 38185982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of inflammatory prognostic index for contrast-induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
    Jiang Y; Luo B; Chen Y; Peng Y; Lu W; Chen L; Lin Y
    Sci Rep; 2024 Jul; 14(1):15861. PubMed ID: 38982273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
    Barbieri L; Verdoia M; Schaffer A; Cassetti E; Di Giovine G; Marino P; Suryapranata H; De Luca G
    Diabetes Res Clin Pract; 2014 Dec; 106(3):458-64. PubMed ID: 25458324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remote ischemic preconditioning reduces the incidence of contrast-induced nephropathy in patients undergoing coronary angiography/intervention: Systematic review and meta-analysis of randomized controlled trials.
    Pranata R; Tondas AE; Vania R; Toruan MPL; Lukito AA; Siswanto BB
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1200-1212. PubMed ID: 31912996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
    Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender Difference in the Risk of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention.
    Barbieri L; Verdoia M; Nardin M; Marino P; Suryapranata H; De Luca G;
    Angiology; 2017 Jul; 68(6):542-546. PubMed ID: 27662891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography.
    Kanbay M; Siriopol D; Ozdogan E; Afsar B; Ertuglu LA; Grigore M; Sag AA; Kuwabara M; Lanaspa MA; Ortiz A; Johnson RJ; Covic A
    Int Urol Nephrol; 2020 Mar; 52(3):541-547. PubMed ID: 32008199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.
    Zhang H; Fu H; Fu X; Zhang J; Zhang P; Yang S; Zeng Z; Fu N; Guo Z
    BMC Nephrol; 2021 Jun; 22(1):206. PubMed ID: 34078303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
    Barbieri L; Verdoia M; Suryapranata H; De Luca G;
    Int J Cardiol; 2019 Jan; 275():48-52. PubMed ID: 30274753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicorandil Reduces the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography/Intervention - Systematic Review and Meta-Analysis of Randomized Controlled Trials Including GRADE Qualification.
    Pranata R; Vania R; Alkatiri AA; Firman D; Lukito AA
    Cardiovasc Revasc Med; 2020 Sep; 21(9):1121-1127. PubMed ID: 31959562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
    Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
    Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predict value of monitoring changes of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 after coronary angiography and percutaneous coronary intervention on early diagnosis of contrast-induced nephropathy].
    Wang L; Pu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Apr; 42(4):301-4. PubMed ID: 24924456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention.
    Azzalini L; Poletti E; Lombardo F; Laricchia A; Beneduce A; Moscardelli S; Bellini B; Maccagni D; Cappelletti A; Ancona MB; Carlino M; Chieffo A; Colombo A; Montorfano M
    Int J Cardiol; 2019 Sep; 290():59-63. PubMed ID: 31005417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of post-procedural hyponatremia on contrast-induced nephropathy in patients who underwent coronary angiography or percutaneous coronary intervention.
    Gucun M; Kahyaoglu M; Celik M; Guner A; Akyuz O; Yilmaz Y
    Acta Cardiol; 2022 May; 77(3):215-221. PubMed ID: 34032177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Del Rio-Pertuz G; Leelaviwat N; Mekraksakit P; Benjanuwattra J; Nugent K; Ansari MM
    Acta Cardiol; 2023 Oct; 78(8):922-929. PubMed ID: 37171278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of Contrast-Induced Nephropathy in Patients Without Baseline Renal Dysfunction Undergoing Coronary Angiography.
    Chen SQ; Liu Y; Smyth B; Li HL; Sun GL; Chen ZJ; Zhou YL
    Heart Lung Circ; 2019 Jun; 28(6):866-873. PubMed ID: 29960836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
    Barbieri L; Verdoia M; Marino P; Suryapranata H; De Luca G;
    Eur J Prev Cardiol; 2016 Jun; 23(9):931-7. PubMed ID: 26525064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous coronary intervention causes increase of serum cystatin C concentration even in the patients with a low risk of contrast-induced nephropathy.
    Tanaga K; Tarao K; Nakamura Y; Inoue T; Jo K; Ishikawa T; Miyazaki A
    Cardiovasc Interv Ther; 2012 Sep; 27(3):168-73. PubMed ID: 22692693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors of contrast-induced nephropathy after percutaneous coronary intervention: a retrospective analysis.
    Wang J; Zhang C; Liu Z; Bai Y
    J Int Med Res; 2021 Apr; 49(4):3000605211005972. PubMed ID: 33878914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.